TY - JOUR
T1 - High-dose atorvastatin reduces periodontal inflammation
T2 - A novel pleiotropic effect of statins
AU - Subramanian, Sharath
AU - Emami, Hamed
AU - Vucic, Esad
AU - Singh, Parmanand
AU - Vijayakumar, Jayanthi
AU - Fifer, Kenneth M.
AU - Alon, Achilles
AU - Shankar, Sudha S.
AU - Farkouh, Michael
AU - Rudd, James H.F.
AU - Fayad, Zahi A.
AU - Van Dyke, Thomas E.
AU - Tawakol, Ahmed
N1 - Funding Information:
Merck & Co., Inc. provided funding for the study. The statistical analysis was conducted with consult from Harvard Catalyst which is supported by National Center for Research Resources and the National Center for Advancing Translational Sciences (NIH Award 8UL1TR000170-05 ). Drs. Alon and Shankar are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Dr. Alon owns stock in Merck Sharp & Dohme Corp. Dr. Farkouh's institution received grants from Merck Sharp & Dohme Corp . Dr. Rudd is supported by the NIHR Cambridge Biomedical Research Center . Drs. Fayad and Tawakol received consulting fees and their institutions received grants from Roche and Merck Sharp & Dohme Corp . All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Subramanian and Emami contributed equally to this work. Drs. Van Dyke and Tawakol also contributed equally to this work.
PY - 2013/12/24
Y1 - 2013/12/24
N2 - Objectives The purpose of this study was to test whether high-dose statin treatment would result in a reduction in periodontal inflammation as assessed by 18F-fluorodeoxyglucose positron emission tomography (FDG-PET)/computed tomography (CT). Background Periodontal disease (PD) is an independent risk factor for atherosclerosis. Methods Eighty-three adults with risk factors or with established atherosclerosis and who were not taking high-dose statins were randomized to atorvastatin 80 mg vs. 10 mg in a multicenter, double-blind trial to evaluate the impact of atorvastatin on arterial inflammation. Subjects were evaluated using FDG-PET/CT at baseline and at 4 and 12 weeks. Arterial and periodontal tracer activity was assessed while blinded to treatment allocation, clinical characteristics, and temporal sequence. Periodontal bone loss (an index of PD severity) was evaluated using contrast-enhanced CT images while blinded to clinical and imaging data. Results Seventy-one subjects completed the study, and 59 provided periodontal images for analysis. At baseline, areas of severe PD had higher target-to-background ratio (TBR) compared with areas without severe PD (mean TBR: 3.83 [95% confidence interval (CI): 3.36 to 4.30] vs. 3.18 [95% CI: 2.91 to 3.44], p = 0.004). After 12 weeks, there was a significant reduction in periodontal inflammation in patients randomized to atorvastatin 80 mg vs. 10 mg (ΔTBR 80 mg vs. 10 mg group: mean -0.43 [95% CI: -0.83 to -0.02], p = 0.04). Between-group differences were greater in patients with higher periodontal inflammation at baseline (mean -0.74 [95% CI: -1.29 to -0.19], p = 0.01) and in patients with severe bone loss at baseline (-0.61 [95% CI: -1.16 to -0.054], p = 0.03). Furthermore, the changes in periodontal inflammation correlated with changes in carotid inflammation (R = 0.61, p < 0.001). Conclusions High-dose atorvastatin reduces periodontal inflammation, suggesting a newly recognized effect of statins. Given the concomitant changes observed in periodontal and arterial inflammation, these data raise the possibility that a portion of that beneficial impact of statins on atherosclerosis relate to reductions in extra-arterial inflammation, for example, periodontitis. (Evaluate the Utility of 18FDG-PET as a Tool to Quantify Atherosclerotic Plaque; NCT00703261)
AB - Objectives The purpose of this study was to test whether high-dose statin treatment would result in a reduction in periodontal inflammation as assessed by 18F-fluorodeoxyglucose positron emission tomography (FDG-PET)/computed tomography (CT). Background Periodontal disease (PD) is an independent risk factor for atherosclerosis. Methods Eighty-three adults with risk factors or with established atherosclerosis and who were not taking high-dose statins were randomized to atorvastatin 80 mg vs. 10 mg in a multicenter, double-blind trial to evaluate the impact of atorvastatin on arterial inflammation. Subjects were evaluated using FDG-PET/CT at baseline and at 4 and 12 weeks. Arterial and periodontal tracer activity was assessed while blinded to treatment allocation, clinical characteristics, and temporal sequence. Periodontal bone loss (an index of PD severity) was evaluated using contrast-enhanced CT images while blinded to clinical and imaging data. Results Seventy-one subjects completed the study, and 59 provided periodontal images for analysis. At baseline, areas of severe PD had higher target-to-background ratio (TBR) compared with areas without severe PD (mean TBR: 3.83 [95% confidence interval (CI): 3.36 to 4.30] vs. 3.18 [95% CI: 2.91 to 3.44], p = 0.004). After 12 weeks, there was a significant reduction in periodontal inflammation in patients randomized to atorvastatin 80 mg vs. 10 mg (ΔTBR 80 mg vs. 10 mg group: mean -0.43 [95% CI: -0.83 to -0.02], p = 0.04). Between-group differences were greater in patients with higher periodontal inflammation at baseline (mean -0.74 [95% CI: -1.29 to -0.19], p = 0.01) and in patients with severe bone loss at baseline (-0.61 [95% CI: -1.16 to -0.054], p = 0.03). Furthermore, the changes in periodontal inflammation correlated with changes in carotid inflammation (R = 0.61, p < 0.001). Conclusions High-dose atorvastatin reduces periodontal inflammation, suggesting a newly recognized effect of statins. Given the concomitant changes observed in periodontal and arterial inflammation, these data raise the possibility that a portion of that beneficial impact of statins on atherosclerosis relate to reductions in extra-arterial inflammation, for example, periodontitis. (Evaluate the Utility of 18FDG-PET as a Tool to Quantify Atherosclerotic Plaque; NCT00703261)
KW - atherosclerosis
KW - imaging
KW - inflammation
KW - nuclear medicine
KW - statins
UR - http://www.scopus.com/inward/record.url?scp=84890627997&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2013.08.1627
DO - 10.1016/j.jacc.2013.08.1627
M3 - Article
AN - SCOPUS:84890627997
SN - 0735-1097
VL - 62
SP - 2382
EP - 2391
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 25
ER -